RxDoctor Payments Data

Magen Heide, MD

Internal Medicine · Greenville, SCNPI 1467956797

Payments from drug & device makers

$2,121in general payments, 2019–2025

Across 99 payments — averaging $21.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$756
  • Lilly USA, LLC$435
  • GSK$145
  • Exact Sciences$134
  • AstraZeneca$112
  • Dexcom, Inc.$93
  • plus $446 from 12 others

What the payments were for

  • Food & beverage$2,02495%
  • Education$975%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,121 in reported general payments places this provider in the 75th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$131,549
Medicare patients
307
Services billed
1,659

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban57$64,833
JardianceEmpagliflozin44$63,452
OzempicSemaglutide42$60,404
MounjaroTirzepatide27$32,379
MyrbetriqMirabegron22$18,601
Repatha SureclickEvolocumab15$14,937
Tresiba Flextouch U-100Insulin Degludec20$10,538
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate14$3,844
Estradiol53$3,030
Levothyroxine Sodium248$2,862
Rosuvastatin Calcium205$2,536
Duloxetine Hcl101$2,238
Atorvastatin Calcium245$2,138
Potassium Chloride30$2,134
Metoprolol Succinate109$1,952

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$17$64,83357 claims
Novo NordiskOzempic$756$60,40442 claims
Lilly USA, LLCMounjaro$435$32,37927 claims
Astellas Pharma US IncMyrbetriq$56$18,60122 claims
AbbVieSynthroid$14$1,59919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →